Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses
of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).